Auna S.A. Q2 2026 Earnings Call Summary

Auna S.A. reported Q2 2026 revenue growth of 9%, driven by high-complexity services, with adjusted EBITDA declining 9% due to investment costs. Management reaffirmed full-year revenue guidance of 12% growth and expects EBITDA growth at the low end of 10-14%. Free cash flow increased 181% due to working capital management. The company faces short-term penalties in Peru but anticipates improvements in profitability and cash flow.

Original reporting
Published Aug 20, 2026, 8:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 20, 2026, 9:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Auna S.A. Q2 2026 Earnings Call Summary — source image
Decision brief

The 30-second read

$AUNANeutralMed
01

Why it matters

Earnings release provides fresh financial metrics and guidance, influencing investor expectations.

02

Market read

First report of Q2 results and FY guidance; material for investors in emerging‑market healthcare.

03

What to watch

FX hedge reset benefits and new ICU capacity additions may improve cash flow beyond current guidance.

Relevance 7/10Novelty 7/10Timing: post-earnings Q2 2026 release

Background

Auna S.A. provides integrated health services across Mexico, Colombia, and Peru, listed on NYSE.

Company-level read

Ticker impact

$AUNANeutralMedium confidence
Context

Q2 2026 earnings release with revenue growth, adjusted EBITDA decline, and updated full-year guidance.

Expected impact

Potential short-term price dip on margin decline, long-term support from reaffirmed revenue guidance.

Evidence & confidence

Guidance confirms growth trajectory; however, EBITDA contraction and penalties may weigh on valuation.

Market effects

Highlights recovery trends in Latin American healthcare services and risk‑sharing contracts.

Positive signal for Mexico and Colombia health markets; Peru penalties may temper local sentiment.

Limited to emerging‑market health sector investors.

Counterpoint

Margin pressures and billing penalties could signal deeper operational issues, suggesting a sell stance.

Key entities

  • Auna S.A.

    Latin American health services provider.

Related articles

$AUNAMed

Auna S.A. (AUNA) Stock Falls on Q3 2026 Earnings

Auna S.A. (AUNA) reported Q3 2026 revenue of $384.7M, up 19.4% YoY, with net income falling 57.4% to $5.9M. Operating cash flow rose 38.9% to $77.6M. Insiders made 6 purchases and 1 sale in the past 6 months. Hedge funds showed mixed activity, with some increasing and others decreasing positions.

$AUNAMed

AUNA S.A. (AUNA): Financial results for Q3 2026

AUNA S.A. (AUNA) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Auna Announces 3Q26 Financial Results Auna reports 10% FX-Neutral Revenue Growth and Continued Strong Cash Generation in 3Q2026; Mexico Returns to Year-over-Year Adjusted EBITDA Growth; Profitability Pressured by Specific Headwinds in Colombia and Peru Leverage Impro

$AUNAHigh

Why is Auna stock dropping today?

Auna SAA ADR stock fell 9.2% to $4.91 after revising its 2026 profitability outlook, citing higher cancer diagnosis costs in Colombia. The company maintained its revenue growth target but saw a sell-off amid broader market declines. The stock dropped to a session low of $4.55, nearing its 52-week low of $4.09.

$AUNAMed

Auna (AUNA) Q2 2026 Earnings Call Transcript

Auna (AUNA) reported Q2 2026 results with 9% revenue growth driven by volume and higher complexity services. Adjusted EBITDA declined 9% due to margin pressures in Mexico and Colombia, and billing penalties in Peru. Mexico saw 7% surgery and 20% oncology volume growth, while Peru achieved 8% revenue growth. Colombia's adjusted EBITDA increased 18% sequentially. Leverage decreased to 3.6x, and cash increased 43% year-over-year.